Chemotherapy-Induced Neutropenia Treatment Market Research Report Information By Type (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Mylan N.V.

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE

6.1. Overview

6.2. Antibiotic Therapy

6.3. Granulocyte Colony-Stimulating Factor Therapy (G-CSF)

6.4. Granulocyte Transfusion

6.5. Others

7. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.2. Hospital Pharmacies

7.3. Retail Pharmacies

7.4. Online Pharmacies

8. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY REGION

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Chemotherapy-Induced Neutropenia Treatment for Medical Devices Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Chemotherapy-Induced Neutropenia Treatment for Medical Devices Market,

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2023

9.8.2. Major Players R&D Expenditure. 2023

10. COMPANY PROFILES

10.1. AMGEN INC.

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Spectrum Pharmaceuticals, Inc.

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Products Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Teva Pharmaceutical Industries Ltd.

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Products Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Sanofi

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Products Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Pfizer Inc.

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Products Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Novartis AG

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Products Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Mylan N.V.

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Products Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Biogen Inc.

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Products Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. JOHNSON & JOHNSON

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Products Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. MERCK & CO., INC.

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Products Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 5 NORTH AMERICA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 7 US: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 8 US: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 9 CANADA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 10 CANADA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 3 GERMANY: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 5 FRANCE: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 6 FRANCE: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 7 ITALY: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 8 ITALY: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 9 SPAIN: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 10 SPAIN: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 11 UK: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 12 UK: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 13 REST OF EUROPE: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 14 REST OF EUROPE: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 15 ASIA-PACIFIC: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 16 ASIA-PACIFIC: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 17 JAPAN: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 18 JAPAN: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 19 JAPAN: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 20 CHINA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 21 INDIA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 22 INDIA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 23 AUSTRALIA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 24 AUSTRALIA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 25 SOUTH KOREA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 26 SOUTH KOREA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 27 REST OF ASIA-PACIFIC: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 28 REST OF ASIA-PACIFIC: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 29 REST OF THE WORLD: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 30 REST OF THE WORLD: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 31 MIDDLE EAST: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 32 MIDDLE EAST: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 33 AFRICA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 34 AFRICA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 35 LATIN AMERICA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 36 LATIN AMERICA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET

FIGURE 4 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SHARE (%), BY TYPE, 2023

FIGURE 5 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023

FIGURE 6 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SHARE (%), BY REGION, 2023

FIGURE 7 NORTH AMERICA: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 EUROPE: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 ASIA-PACIFIC: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 REST OF THE WORLD: CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT FOR MEDICAL DEVICES MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 12 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 AMGEN INC.: SWOT ANALYSIS

FIGURE 14 SPECTRUM PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 SPECTRUM PHARMACEUTICALS, INC.: SWOT ANALYSIS

FIGURE 16 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 18 SANOFI: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 SANOFI: SWOT ANALYSIS

FIGURE 20 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 PFIZER INC.: SWOT ANALYSIS

FIGURE 22 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 NOVARTIS AG: SWOT ANALYSIS

FIGURE 24 MYLAN N.V.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 MYLAN N.V.: SWOT ANALYSIS

FIGURE 26 BIOGEN INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 BIOGEN INC.: SWOT ANALYSIS

FIGURE 28 JOHNSON & JOHNSON: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 JOHNSON & JOHNSON: SWOT ANALYSIS

FIGURE 30 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 MERCK & CO., INC.: SWOT ANALYSIS